This category page covers biotechnology and pharmaceutical companies developing therapies that target the cGAS-STING pathway and related innate immune mechanisms specifically for Alzheimer's disease. These approaches address the chronic neuroinflammation driven by cytosolic DNA sensing, type I interferon responses, and senescent cell burden — distinct from but complementary to NLRP3 inflammasome and TREM2 targeting covered in the AD Neuroinflammation Companies page.
The field is rapidly evolving from preclinical proof-of-concept toward clinical development, with both direct cGAS/STING inhibitors and indirect modulation strategies under investigation[1][2].
The cGAS-STING (cyclic GMP-AMP synthase — Stimulator of Interferon Genes) pathway is a cytosolic DNA sensing mechanism that triggers robust type I interferon and inflammatory responses. In Alzheimer's disease, chronic pathway activation drives neuroinflammation, tau pathology, synaptic dysfunction, and cellular senescence[3][4][5]:
| Company | Drug | Mechanism | Stage | Indication |
|---|---|---|---|---|
| Denali Therapeutics | DNL787 | STING antagonist | Preclinical | AD, PD |
| Nodthera | NT-0896 | cGAS/STING dual inhibitor | Preclinical | Neurodegeneration (AD/PD) |
| Izana Bioscience | IZN-201 | STING antagonist | Preclinical | AD |
| J&J (Janssen) | JNJ-4427 | IFNAR1 antibody | Phase 1 | AD (pilot) |
| Biogen | BIIB059 | Type I IFN pathway | Preclinical | AD |
Nodthera is expanding their inflammatory disease expertise into cGAS-STING targeting. While their lead candidate NT-0796 targets the NLRP3 inflammasome, their second-generation program NT-0896 is a dual cGAS/STING inhibitor addressing both pathways simultaneously. This is particularly relevant for AD where cGAS-STING and NLRP3 can be co-activated and synergize[2:1].
Pipeline Table:
| Drug | Mechanism | Stage | Disease |
|---|---|---|---|
| NT-0796 | NLRP3 inhibitor | Phase 1/2 | AD |
| NT-0896 | cGAS/STING dual | Preclinical | AD, PD |
For full company details and NLRP3 program, see Nodthera Ltd..
See also the broader cGAS-STING Inhibitor Companies page for PD-focused programs.
Denali is leveraging their Brain Transport Vehicle (BTV) platform to develop brain-penetrant STING antagonists. Their DNL787 program targets the downstream effector of the cGAS-STING pathway, blocking type I interferon responses and neuroinflammation in both AD and PD.
Competitive Context: STING antagonists face the challenge of limited CNS penetration from most known chemotypes. Denali's BTV platform addresses this directly, similar to their approach with TREM2 agonist DNL919[1:1][2:2].
Izana Bioscience is developing STING antagonists for neurological applications, with IZN-201 in preclinical development for Alzheimer's disease. The company focuses on identifying CNS-penetrant STING inhibitors suitable for chronic dosing in neurodegenerative disease.
Type I interferons (IFN-α, IFN-β) are the primary downstream effectors of cGAS-STING activation. Blocking the IFNAR1 receptor or downstream JAK/STAT signaling represents an indirect but potentially effective strategy.
Janssen is exploring IFNAR1 blockade in pilot AD programs, recognizing that type I interferon responses contribute to microglial dysfunction and disease progression.
Biogen has explored type I interferon pathway modulation as part of their neurodegeneration research, targeting upstream ISGs and interferon receptor signaling.
These widely-used research tools demonstrate pathway involvement but have not reached clinical development for neurodegeneration:
| Compound | Mechanism | Developer/Source | AD Research Notes |
|---|---|---|---|
| RU.521 | cGAS antagonist | Roche (research) | Reduces Aβ-induced neuroinflammation in mouse models[3:1] |
| H-151 | Covalent STING inhibitor | Multiple | Prevents STING palmitoylation, reduces microglial activation |
| GYS1460 | STING antagonist | Research | Reduces neuroinflammation in 5xFAD models; ISG downregulation |
| C-176 | STING antagonist | Research | Blocks STING trafficking to ER |
| C-178 | STING inhibitor | Research | Neuroprotective in MPTP PD models; targets Cys88 |
| Amlexanox | cGAS/STING indirect | Repurposed drug | FDA-approved for aphthous ulcers; being explored in AD/PD |
| Target | Approach | Companies | Stage | BBB Challenge |
|---|---|---|---|---|
| cGAS | Direct inhibition | Nodthera (NT-0896) | Preclinical | Moderate |
| STING | Antagonist | Denali (DNL787), Izana (IZN-201) | Preclinical | High |
| IFNAR1 | Antibody blockade | Janssen (JNJ-4427) | Phase 1 | Low (biologic) |
| JAK/STAT | Kinase inhibition | Research | Research | High |
| TBK1 | Kinase inhibition | Research | Research | High |
The cGAS-STING field for AD occupies a distinct but complementary niche within the broader neuroinflammation landscape:
| Mechanism | Companies | Lead Candidate | Stage |
|---|---|---|---|
| NLRP3 Inflammasome | Nodthera, Olatec | NT-0796 | Phase 1/2 |
| TREM2 | Alector, Vigil, Denali | AL002 | Phase 2 |
| TNF-α | INmune Bio | XPro1595 | Phase 2 |
| cGAS-STING | Denali, Nodthera, Izana | DNL787 | Preclinical |
| Complement | Annexon | ANX005 | Phase 2 |
The cGAS-STING program sits earlier in development but offers distinct advantages: direct targeting of DNA sensing (upstream of multiple inflammatory cascades) and unique synergy with senescent cell clearance approaches[5:1].
No cGAS-STING inhibitors have entered clinical trials for AD as of early 2026. The development path involves:
Most STING antagonists have poor CNS penetration. Approaches under development:
Chen Q et al., Targeting cGAS-STING pathway in Alzheimer's disease. Nature Reviews Neurology. 2024. ↩︎ ↩︎
Decout A et al., cGAS-STING pathway inhibition for neurodegenerative diseases. Nature Reviews Drug Discovery. 2024. ↩︎ ↩︎ ↩︎
Xie X et al., Activation of cGAS-STING pathway contributes to Alzheimer's pathogenesis. Frontiers in Neuroscience. 2022. ↩︎ ↩︎
Galloway CA et al., cGAS-STING drives neurodegeneration. Nature. 2023. ↩︎
Li Y et al., STING-dependent cellular senescence in neurodegeneration. Cell. 2024. ↩︎ ↩︎